After Roche, BMS surprises, what does AbbVie need to do to win FTC clearance for Allergan buy?

With mergers and acquisitions come antitrust reviews. And with the U.S. Federal Trade Commission (FTC) cracking down on pharma deals these days, it’s only natural to ask whether AbbVie’s proposed $63 billion acquisition of Allergan could face anti-competition scrutiny, despite across-board complaint from industry watchers over the lack of similarities between the two firms.
Read more...

;